Long term effects of the treatment of polycythemia vera (PV) with recombinant interferon alfa (rIFNα).

被引：0
|
作者：
Silver, RT
Pahuja, M
Klein, J
机构：
[1] New York Presbyterian Hosp, Div Hematol Oncol, New York, NY USA
[2] Weill Cornell Med Ctr, New York, NY USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3205
引用
收藏
页码：741A / 741A
页数：1
相关论文
共 50 条
  • [21] Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
    Hasselbalch, Hans
    Skov, Vibe
    Kjaer, Lasse
    Larsen, Morten Kranker
    Knudsen, Trine A.
    Lucijanic, Marko
    Kusec, Rajko
    CANCERS, 2022, 14 (22)
  • [22] Interferon-alfa2 Treatment of Patients with Polycythemia Vera and Related Neoplasms Influences Deregulated Inflammation and Immune Genes in Polycythemia Vera and Allied Neoplasms
    Skov, Vibe
    Riley, Caroline
    Thomassen, Mads
    Kjaer, Lasse
    Larsen, Thomas Stauffer
    Bjerrum, Ole Weis
    Kruse, Torben A.
    Hasselbalch, Hans Carl
    BLOOD, 2018, 132
  • [23] Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
    Kiladjian, Jean-Jacques
    Klade, Christoph
    Georgiev, Pencho
    Krochmalczyk, Dorota
    Gercheva-Kyuchukova, Liana
    Egyed, Miklos
    Dulicek, Petr
    Illes, Arpad
    Pylypenko, Halyna
    Sivcheva, Lylia
    Mayer, Jiri
    Yablokova, Vera
    Krejcy, Kurt
    Empson, Victoria
    Hasselbalch, Hans Carl
    Kralovics, Robert
    Gisslinger, Heinz
    BLOOD, 2022, 140 : 9663 - 9664
  • [24] Long-term treatment with different regimens of recombinant interferon alfa in chronic hepatitis C
    Podda, M
    Battezzati, PM
    Zuin, M
    Bruno, S
    Gallotti, P
    Borzio, M
    Borzio, F
    Fornari, F
    Lanzini, A
    Salmi, A
    Russo, A
    HEPATOLOGY, 1996, 23 (01) : P215 - P215
  • [25] Polycythemia vera: Updated Onkopedia Guidelines recommend Interferon alfa as preferred First-line Treatment
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [26] Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
    Larsen, Thomas Stauffer
    Iversen, Katrine F.
    Hansen, Esben
    Mathiasen, Anders Bruun
    Marcher, Claus
    Frederiksen, Mikael
    Larsen, Herdis
    Helleberg, Inge
    Riley, Caroline Hasselbalch
    Bjerrum, Ole W.
    Ronnov-Jessen, Dorthe
    Moller, Michael Boe
    de Stricker, Karin
    Vestergaard, Hanne
    Hasselbalch, Hans Carl
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1041 - 1045
  • [27] Polycythemia Vera (PV): Update on Emerging Treatment Options
    Benevolo, Giulia
    Vassallo, Francesco
    Urbino, Irene
    Giai, Valentina
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 209 - 221
  • [28] Long-term therapy with recombinant interferon-gamma (rIFN-γ) for atopic dermatitis
    Schneider, LC
    Baz, Z
    Zarcone, C
    Zurakowski, D
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1998, 80 (03) : 263 - 268
  • [29] Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
    Jean-Jacques Kiladjian
    Christoph Klade
    Pencho Georgiev
    Dorota Krochmalczyk
    Liana Gercheva-Kyuchukova
    Miklos Egyed
    Petr Dulicek
    Arpad Illes
    Halyna Pylypenko
    Lylia Sivcheva
    Jiří Mayer
    Vera Yablokova
    Kurt Krejcy
    Victoria Empson
    Hans C. Hasselbalch
    Robert Kralovics
    Heinz Gisslinger
    Leukemia, 2022, 36 : 1408 - 1411
  • [30] Recombinant Interferon-a Reduces Thrombotic Events in Patients with Polycythemia Vera
    Krichevsky, Spencer
    Abu Zeinah, Ghaith
    Sosner, Claudia
    Jaber, Diana
    Savage, Niamh
    Hoberman, Gabriela
    Ritchie, Ellen K.
    Schafer, Andrew I.
    Silver, Richard T.
    Scandura, Joseph
    BLOOD, 2019, 134
12345